VP2 Stock Overview A specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Valeo Pharma Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Valeo Pharma Historical stock prices Current Share Price €0.005 52 Week High €0.23 52 Week Low €0.0045 Beta 1.6 1 Month Change 0% 3 Month Change -79.59% 1 Year Change -95.10% 3 Year Change -99.01% 5 Year Change n/a Change since IPO -99.33%
Recent News & Updates
Third quarter 2024 earnings released: CA$0.083 loss per share (vs CA$0.069 loss in 3Q 2023) Sep 14
Valeo Pharma Inc. to Report Q3, 2024 Results on Sep 12, 2024 Sep 09
Valeo Pharma Inc. Announces Board Changes Aug 07
Valeo Pharma Inc. Appoints Al Moghaddam as Chief Development Officer and Consequently Steps Down from its Board of Directors Jun 18
New major risk - Revenue and earnings growth Jun 17
Second quarter 2024 earnings released: CA$0.079 loss per share (vs CA$0.077 loss in 2Q 2023) Jun 16 See more updates
Third quarter 2024 earnings released: CA$0.083 loss per share (vs CA$0.069 loss in 3Q 2023) Sep 14
Valeo Pharma Inc. to Report Q3, 2024 Results on Sep 12, 2024 Sep 09
Valeo Pharma Inc. Announces Board Changes Aug 07
Valeo Pharma Inc. Appoints Al Moghaddam as Chief Development Officer and Consequently Steps Down from its Board of Directors Jun 18
New major risk - Revenue and earnings growth Jun 17
Second quarter 2024 earnings released: CA$0.079 loss per share (vs CA$0.077 loss in 2Q 2023) Jun 16
Second quarter 2024 earnings released: CA$0.079 loss per share (vs CA$0.077 loss in 2Q 2023) Jun 16
New major risk - Revenue and earnings growth Jun 14
Valeo Pharma Inc. to Report Q2, 2024 Results on Jun 13, 2024 Jun 06
New major risk - Market cap size Apr 03
Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors Mar 22
First quarter 2024 earnings released: CA$0.08 loss per share (vs CA$0.077 loss in 1Q 2023) Mar 15
Valeo Pharma Inc. to Report Q1, 2024 Results on Mar 14, 2024 Mar 08
Valeo Pharma Inc., Annual General Meeting, Apr 25, 2024 Feb 27
Valeo Pharma Inc. Announces Board Changes Feb 13
No longer forecast to breakeven Feb 07
Full year 2023 earnings released: CA$0.32 loss per share (vs CA$0.32 loss in FY 2022) Jan 30
Valeo Pharma Inc. to Report Q4, 2023 Results on Jan 29, 2024 Jan 23 Valeo Pharma Inc. Announces Chief Financial Officer Changes Nov 21
Valeo Pharma Inc. Announces Appointment of Mr. Richard Lajoie to Board of Directors Nov 08
New major risk - Market cap size Oct 31
New minor risk - Profitability Oct 16
Third quarter 2023 earnings released: CA$0.069 loss per share (vs CA$0.058 loss in 3Q 2022) Sep 14
Valeo Pharma Inc. to Report Q3, 2023 Results on Sep 13, 2023 Sep 08 Valeo Pharma Inc. announced that it has received CAD 4.499999 million in funding from Investissement Québec Sep 01
Less than half of directors are independent Jun 29
Valeo Pharma Inc. Announces Board Appointments Jun 23
Forecast breakeven date pushed back to 2025 Jun 17
Second quarter 2023 earnings released: CA$0.077 loss per share (vs CA$0.063 loss in 2Q 2022) Jun 15
Valeo Pharma Inc. to Report Q2, 2023 Results on Jun 13, 2023 Jun 09
First quarter 2023 earnings released: CA$0.077 loss per share (vs CA$0.074 loss in 1Q 2022) Mar 17 Mar 16
Valeo Pharma Obtains Public Reimbursement for Onstryv in Quebec Feb 08
Full year 2022 earnings released: CA$0.32 loss per share (vs CA$0.20 loss in FY 2021) Feb 01
Valeo Pharma Announces Filing of New Drug Submission-Covid 19 with Health Canada for Sabizabulin for the Treatment of Hospitalized Covid-19 Patients Jan 27
Valeo Pharma Inc. to Report Q4, 2022 Results on Jan 30, 2023 Jan 26
Valeo Pharma Inc. Announces Stepping Down of Frederic Fasano as President and Chief Operating Officer Nov 22
Less than half of directors are independent Nov 16 Valeo Pharma Inc. Revises Revenue Guidance for the Fourth Quarter of 2022
Valeo Pharma Inc. Provides Revenue Guidance for the Fourth Quarter of 2022 Sep 16
Third quarter 2022 earnings released: CA$0.058 loss per share (vs CA$0.042 loss in 3Q 2021) Sep 15
Valeo Pharma Inc. to Report Q3, 2022 Results on Sep 13, 2022 Sep 10
Valeo Pharma Announces Executive Appointments Aug 31
Key Executive recently bought €83k worth of stock Jun 19
Second quarter 2022 earnings released: CA$0.063 loss per share (vs CA$0.028 loss in 2Q 2021) Jun 15
Valeo Pharma Inc. to Report Q2, 2022 Results on Jun 14, 2022 Jun 09
Less than half of directors are independent May 01
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 02
Valeo Pharma Inc., Annual General Meeting, Apr 27, 2022 Feb 26
Valeo Pharma Inc. to Report Q4, 2021 Results on Feb 28, 2022 Feb 22
Valeo Pharma's Hespercotm Now Available At Loblaws, Hesperidin Covid-19 Clinical Trial Results Submitted for Publication Jan 06
Valeo Pharma Inc. announced that it expects to receive CAD 20 million in funding from Investissement Québec, Investment Arm and other investors Nov 25
Key Executive recently bought €63k worth of stock Oct 22
Key Executive recently bought €53k worth of stock Oct 02
Third quarter 2021 earnings released: CA$0.042 loss per share (vs CA$0.028 loss in 3Q 2020) Sep 23
Senior VP & CFO recently bought €67k worth of stock Jul 18
Valeo Pharma Announces Additional Provincial Reimbursement Coverage for Redesca™ and Redesca HP™ Jul 15
Senior VP & CFO recently bought €136k worth of stock Jul 02
Second quarter 2021 earnings released: CA$0.028 loss per share (vs CA$0.015 loss in 2Q 2020) Jul 01
Valeo Pharma Inc. has completed a Composite Units Offering in the amount of CAD 10 million. Jun 30
Valeo Pharma Inc. Announces Commercial Launch of Enerzair Breezhaler and Atectura Breezhaler Jun 23
Valeo Pharma Inc. Announces Outlook for Its Second Quarter Ended April 30, 2021 May 27
Valeo Pharma Inc. announced that it has received CAD 6.645 million in funding Apr 28
President recently bought €117k worth of stock Apr 21
Valeo Pharma Inc. announced that it expects to receive CAD 4 million in funding Apr 16
First quarter 2021 earnings released: CA$0.027 loss per share (vs CA$0.02 loss in 1Q 2020) Apr 02
Full year 2020 earnings released: CA$0.082 loss per share (vs CA$0.073 loss in FY 2019) Feb 26
Valeo Pharma Inc., Annual General Meeting, Apr 28, 2021 Feb 26
New 90-day low: €0.67 Feb 25
Valeo Pharma Inc. to Report Q4, 2020 Results on Feb 24, 2021 Feb 20
Valeo Pharma Inc. and Ingenew Pharma Inc. Announce HespercoTM Capsules Feb 18
New 90-day high: €0.94 Jan 23
Valeo Pharma Appoints Frederic Fasano to the Newly Created Position of President and Chief Operating Officer Jan 20
New 90-day high: €0.80 Jan 06
Valeo Pharma Announces Health Canada Approval for Redesca™ and Redesca Hp™ Dec 10
Valeo Pharma Announces Amikacin Approval in Canada and U.S. Launch of Ethacrynate Sodium Nov 13
Valeo Pharma Announces That Hesperco™ Has Started Shipping Oct 14
Third quarter earnings released Sep 30
Valeo Pharma Inc. to Report Q3, 2020 Results on Sep 29, 2020 Sep 25
Valeo Pharma Inc. has completed a Composite Units Offering in the amount of CAD 6 million. Sep 11 Shareholder Returns VP2 DE Pharmaceuticals DE Market 7D 0% -1.7% -1.6% 1Y -95.1% -15.8% 6.8%
See full shareholder returns
Return vs Market: VP2 underperformed the German Market which returned 7.1% over the past year.
Price Volatility Is VP2's price volatile compared to industry and market? VP2 volatility VP2 Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine VP2's volatility change over the past year.
About the Company Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson’s disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic.
Show more Valeo Pharma Inc. Fundamentals Summary How do Valeo Pharma's earnings and revenue compare to its market cap? VP2 fundamental statistics Market cap €493.38k Earnings (TTM ) -€21.80m Revenue (TTM ) €36.22m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) VP2 income statement (TTM ) Revenue CA$53.38m Cost of Revenue CA$41.36m Gross Profit CA$12.02m Other Expenses CA$44.14m Earnings -CA$32.12m
Last Reported Earnings
Jul 31, 2024
Earnings per share (EPS) -0.33 Gross Margin 22.51% Net Profit Margin -60.18% Debt/Equity Ratio -110.1%
How did VP2 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/11/21 01:43 End of Day Share Price 2024/10/02 00:00 Earnings 2024/07/31 Annual Earnings 2023/10/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Valeo Pharma Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Neil Linsdell iA Capital Markets Chelsea Stellick iA Capital Markets Scott McAuley Paradigm Capital, Inc.
Show 0 more analysts 
